Drug Target Review

JULY 13, 2023

In this article, we will delve into the world of condensate biology and explore the groundbreaking research projects undertaken to discover the potential they hold for diseases such as amyotrophic lateral sclerosis ( ALS ) and colorectal cancer. Klein notes the importance of Dewpoint’s disease-agnostic approach.

Disease 98

Disease Small Molecule Cell Biology Drugs 98

PPD

JANUARY 15, 2025

As clinical trials become increasingly complex, particularly in decentralized trials and rare disease studies, sponsors experience increased challenges in site selection, forecasting and resourcing, and patient recruitment and enrollment. Get in touch. Discover how AI is used to optimize key aspects of clinical trial management.

Clinical Trials 95

Clinical Trials Trials Clinical Research Drug Development 95

Drug Discovery Today

DECEMBER 3, 2021

Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech companies has announced a breakthrough in laboratory trials of a new drug to treat COVID-19 and new variants of the disease, such as the Omicron variant.

Laboratories 113

Laboratories Drugs Disease Trials 113

KIF1A

MARCH 2, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. Animal models have given researchers profound insights into disease, assisting in the creation and testing of new therapies that have changed lives across the world.

Laboratories 119

Laboratories Cell Biology Disease Research 119

Conversations in Drug Development Trends

JANUARY 24, 2024

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment.

Trials 75

Trials Disease Clinical Trials Clinical Research 75

Broad Institute

JUNE 18, 2024

The test, developed by a team from the Broad Institute of MIT and Harvard and Princeton University, and supported by the US Centers for Disease Control and Prevention, uses CRISPR to distinguish between the two main types of seasonal flu, influenza A and B, as well as seasonal flu subtypes H1N1 and H3N2. The Journal of Molecular Diagnostics.

Virus 144

Virus RNA Laboratories Medical Schools 144

Precision for Medicine

APRIL 7, 2023

The custom-designed laboratory accommodates the growth in demand for advanced digital pathology and imaging capabilities, expertise in molecular sciences and a wide array of sequencing technologies. The expansion significantly increases the sample processing capacity of the laboratory. Senior Vice President at Precision for Medicine.

Laboratories 52

Laboratories Clinical Research Clinical Trials Cell Biology 52

Codon

NOVEMBER 3, 2024

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. But even now, more than a century later, TB remains the deadliest infectious disease on Earth, killing about 1.2 million people every year.

Vaccine 102

Vaccine Trials Therapies Treatment 102

Conversations in Drug Development Trends

NOVEMBER 12, 2024

By Amy Raymond, PhD, PMP, Executive Director, Therapeutic Strategy Lead, Rare Disease Cell and gene therapies (CGTs) include cutting-edge approaches that offer the hope of a healthier, happier, and better tomorrow for a wide range of patient populations. Modifying and expanding the cells in a GMP laboratory.

Therapies 72

Therapies Clinical Supply Clinical Trials Trials 72

Drug Target Review

SEPTEMBER 9, 2024

functions to reset the immune system and potentially provide remission for allergic diseases? In allergic diseases, APCs identify and present unknown antigens to the immune system. This can lead to inadequate long-term effectiveness with low rates of disease remission. They also require frequent administration.

Disease 64

Disease Immune Response Clinical Trials Treatment 64

Elrig

MARCH 25, 2025

It will also cover recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, the use of targeted delivery to reach disease-relevant tissues as well as success stories in bringing therapeutic oligonucleotides to the clinic.

RNA 59

RNA Bioinformatics Science Pharmacokinetics 59

NIOSH Science Blog: Drugs

SEPTEMBER 6, 2023

NIOSH’s National Personal Protective Technology Laboratory (NPPTL) mission is to prevent disease, injury, and death for the millions of workers who rely on personal protective technology. occupational settings. One of NPPTL’s main responsibilities is

Laboratories 100

Laboratories Disease 100

Drug Target Review

MARCH 19, 2024

In other words, a disease state may cause a change in vitamin A levels rather than the vitamin A levels causing a change in disease state. Again, in this circumstance adding the vitamin will not help therapeutically with the disease state. Secondly, it’s difficult to separate causation from reverse causation.

Laboratories 105

Laboratories Bioinformatics International Research Laboratories 105

Drug Target Review

JANUARY 2, 2024

We are studying the placement of organelles within cells and how they communicate to help better treat disease,” said Coskun. Scrutinising these distinctions aids scientists in comprehending cellular operations, thereby fostering enhanced therapeutic approaches for diverse diseases.

RNA 128

RNA Immune Response Therapies Disease 128

DrugBank

MARCH 28, 2024

Space bioscience also has the ability to accelerate disease and cell research at an advanced pace due to the speed in which these stressors affect tissue cells in space. Vector Space Biosciences is pioneering this effort by devising countermeasures against the detrimental impacts of space travel on human physiology.

DNA 144

DNA Laboratories Disease Engineering 144

Drug Target Review

DECEMBER 11, 2024

This shift in focus is especially critical in toxicology, where accurate target analysis plays a vital role in identifying toxic effects and ensuring patient safety, particularly as the field transitions from traditional drugs to the promising realm of biotherapeutics, especially for rare diseases.

International 52

International Laboratories Drugs Pharmacokinetics 52

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. At least nine laboratories outside the U.S. At least nine laboratories outside the U.S.

DNA 102

DNA Laboratories Hospitals Virus 102

BMG Labtech

MARCH 11, 2024

Enzyme-Linked Immunosorbent Assays (ELISAs) are an essential technique in today’s laboratory with many applications in the life sciences. 1,2 Anton Schuurs and Bauke van Weemen at the research laboratories of NV Organon, Oss, the Netherlands developed a similar technique which was also published in 1971.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

sptlabtech

JUNE 9, 2023

The field of genomics has witnessed a revolutionary transformation, leading to a better understanding of health and disease, as well the emergence of personalized medicine to improve therapeutic outcomes. Enter firefly ®. What benefits can you expect to see from making the switch to automated liquid handling with firefly?

Laboratories 98

Laboratories Molecular Biology DNA Engineering 98

Broad Institute

OCTOBER 21, 2024

In previous work on a small number of patient samples from MGH’s clinical microbiology laboratory, the research team showed that GoPhAST-R can determine antibiotic susceptibility less than four hours after bacteria are detected in a blood culture, compared to 28-40 hours using standard clinical laboratory methods.

RNA 115

RNA Hospitals Laboratories Medical Schools 115

PPD

JUNE 24, 2024

Big data: The role of big data and real-world data (RWD) will continue to expand, providing deeper insights into patient behaviors, disease patterns and treatment effectiveness in real-world settings. These cutting-edge tools offer promising prospects for monitoring physiological responses to vaccines as well as incident disease events.

Vaccine 97

Vaccine Trials Clinical Trials Laboratories 97

The Pharma Data

FEBRUARY 23, 2022

Autoimmune diseases are triggered when the immune system malfunctions and attacks the body’s own structures. Although there is not, as yet, any cure for such diseases, their progression can be slowed down by therapeutic measures. JAK inhibitors are used to treat various autoimmune diseases, such as rheumatoid arthritis.

Disease 52

Disease Laboratories Research Therapies 52

PLOS: DNA Science

MAY 16, 2024

That’s thanks to accelerated genome sequencing technologies, expanded laboratory capabilities, and interacting infrastructure on a global level. Had we grown complacent in a world freed from a list of once-deadly infectious diseases, thanks largely to vaccines and other public health measures? COVID clearly caught us off guard.

Virus 98

Virus DNA RNA Vaccine 98

Broad Institute

AUGUST 31, 2023

Related News Next generation prime editing systems move closer to possible therapeutic applications New CRISPR genome editing system offers a wide range of versatility in human cells Prime editing technologies allow scientists to precisely edit the genome in a variety of ways and could one day be used to treat genetic diseases.

DNA 145

DNA Engineering RNA Laboratories 145

KIF1A

MARCH 9, 2024

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. During her undergraduate studies, she worked on heart disease research in Chi Kueng Lam’s laboratory at the University of Delaware.

Laboratories 111

Laboratories Science Research Disease 111

SCIENMAG: Medicine & Health

JULY 26, 2023

Lymph nodes are one of the body’s first lines of defense against disease. Credit: Beyaz lab/Cold Spring Harbor Laboratory Lymph nodes are one of the body’s first lines of […] Immune cells are dispatched from these biological police stations to fight off intruders.

Laboratories 73

Laboratories Disease 73

The Pharma Data

AUGUST 5, 2021

and described today in eLife, may help expedite the process by helping scientists find promising, existing drugs that might be repurposed for these diseases. Further studies are now necessary to validate that these drugs can be repurposed for this disease. The database, called NICEdrug.ch The researchers have made the NICEdrug.ch

Disease 52

Disease Drugs Laboratories Engineering 52

Conversations in Drug Development Trends

DECEMBER 19, 2024

At the recent World Orphan Drug Congresses (WODC) in Europe and the United States, Worldwide Clinical Trials Derek Ansel , Vice President, Therapeutic Strategy Lead, Rare Disease, facilitated roundtable discussions to explore the operational challenges and ethical barriers surrounding genetic testing.

Clinical Trials 52

Clinical Trials Regulations Drugs Trials 52

Drug Target Review

NOVEMBER 1, 2023

2 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. 1-5 Implication of ATX in a large range of human diseases have been highlighted by both fundamental research and clinical trials. Mediators of Inflammation. 2017;2017:1–15. Herr DR, Chew WS, Satish RL, Ong WY.

Clinical Trials 134

Clinical Trials Trials Small Molecule Disease 134

KIF1A

JUNE 17, 2023

Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. #ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. What’s a pre-print?

Laboratories 98

Laboratories Therapies Disease Research 98

Broad Institute

APRIL 25, 2024

He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Blood and urine samples from the man were waiting for Happi in his lab. Happi felt chilled. They called the idea Sentinel.

Virus 132

Virus Hospitals Disease Government 132

FDA Law Blog: Biosimilars

FEBRUARY 2, 2024

Most of these reclassified tests will supposedly be infectious disease and companion diagnostic IVDs. The announcement also states that FDA expects most future companion diagnostic and infectious disease IVDs would be regulated as class II devices, even if they are novel and require de novo classification.

FDA 116

FDA Regulations Laboratories Disease 116

The Pharma Data

OCTOBER 1, 2021

Deucravacitinib demonstrated efficacy no matter baseline characteristics, including weight , disease severity and former treatment with biologic or non-biologic therapies. Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, rheumatoid arthritis , lupus and inflammatory bowel disease.

Disease 52

Disease Laboratories Clinical Pharmacology Treatment 52

KIF1A

MAY 24, 2023

In this blog post, KIF1A.ORG Chief Science Officer Dr. Dominique Lessard describes a unique cross disciplinary experience with multiple scientific stakeholders in the rare disease space, all focused around our holistic understanding of KAND. How do we move the needle to make patient voices and experiences the center of scientific discovery?

Disease 98

Disease Laboratories Research Science 98

Conversations in Drug Development Trends

DECEMBER 12, 2022

Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinical trial advancement. What is the difference between a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory vs a research laboratory?

Clinical Trials 52

Clinical Trials Trials Laboratories Research Laboratories 52

PPD

MARCH 13, 2024

In combination, they provide confidence in dose escalation or protocol adaptation decisions, which ultimately benefit patients who often have critical and life-limiting diseases. For patients with a rare disease entering a Phase Ib clinical trial, confidence in the management of their time and safety is paramount.

Clinical Development 98

Clinical Development Clinical Trials Therapies Trials 98

Broad Institute

MAY 30, 2023

The new model, dubbed Geneformer, learns from massive amounts of data on gene interactions from a broad range of human tissues and transfers this knowledge to make predictions about how things might go wrong in disease. Theodoris and her team used Geneformer to shed light on how heart cells go awry in heart disease.

Disease 98

Disease Research Laboratories Science 98